Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

3



Gefitinib induced convulsions: a rare case report

Atul J. Rajpara, Neeta J. Kanani.

Abstract
Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor is used as first-line therapy for non-small cell lung cancer and sometimes also used to treat the other metastatic carcinomas. Diarrhoea and pustular/papular rash occur in ~50% of patients taking gefitinib. Other side effects include dry skin, nausea, vomiting, pruritus, anorexia, and fatigue, but central side effects, especially convulsions are very rare. Here, we report a rare case of 60 years old female patient, a known case of carcinoma uterus with local metastasis and on high dose gefitinib (500 mg/day) treatment for 3 months, who developed generalized tonic-clonic seizure with frothing in mouth and postictal confusion. The dose of suspected medication was reduced to 250 mg/day and patient was given standard care for this adverse drug reaction.

Key words: Drug induced convulsions, Gefitinib, Rare adverse drug reaction



Share this Article


Advertisement
American Journal of Research in Medical Sciences

SUBMIT YOUR ARTICLE NOW




ScopeMed Home
Follow ScopeMed on Twitter
BiblioCAM
Article Tools
eJPort Journal Hosting
About ScopeMed
License Information
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.
Scopemed Buttons